echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Acromegaly: Is it more common for men or women?

    Acromegaly: Is it more common for men or women?

    • Last Update: 2021-05-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Yimaitong compiles and organizes, please do not reprint without authorization.

    Recently, a study published in the journal Clin Endocrinol showed that: when acromegaly is diagnosed, there is no obvious gender difference in the ratio of male to female, but compared with male patients, female patients are older at diagnosis.
    IGF- The I concentration is lower and there is a longer diagnosis delay.

     Regarding the gender differences in the onset of acromegaly, previous studies have expressed different expressions.
    Acromegaly is a rare disease caused by chronic hypersecretion of growth hormone caused by pituitary adenomas.

    The latest foreign data based on population studies show that the prevalence of this disease is 85-137 cases/million people, and the incidence is about 4 cases/million person-years.

    The natural course of growth hormone secreting pituitary adenomas is affected by individual differences, has different clinical, radiological, and histopathological subtypes, and the onset is insidious, usually with a delay of 5-10 years in diagnosis.

     Unlike other hormone-secreting pituitary tumors, which account for a large proportion of women, it is not clear whether the incidence and prevalence of acromegaly are different between men and women.

    Two recent reviews concluded that acromegaly is more common in women, but there are significant differences in the gender distribution of different age groups.
    There are also reports that women are dominant, and women are often older at the time of diagnosis.

     Are there gender differences in the prevalence of acromegaly? Researchers from Denmark explored this issue.

    Study description The researchers conducted a total of 2 studies, one was a cohort study based on acromegaly cases (n=596), and the other was a meta-analysis of 40 studies.

    The researchers evaluated gender differences in terms of prevalence, age at diagnosis, delay in diagnosis, size of pituitary adenoma, insulin-like growth factor 1 (IGF-I) and growth hormone (GH) levels.

    There is no significant difference in the proportion of males and females.
    1.
    The cohort study of acromegaly patients had similar gender ratios at the time of diagnosis (49.
    6% of women), and the average age of men and women at diagnosis was also the same (male: 48.
    2 years, Female: 47.
    2 years old, P=0.
    4), and remained unchanged during the observation period.

    There is also no significant difference in the sex ratio of patients ≤25 years old and ≤18 years old.

     However, compared with men, women have significantly lower levels of IGF-ISDS, while growth hormone and pituitary adenoma size do not differ between men and women.

     2.
    Meta analysis The weighted percentage of women in each study is 53.
    3% (95% CI 51.
    5~55.
    2), and the heterogeneity is large (I^2=85%).

    The average age difference between men and women was 3.
    1 years (95% CI 1.
    9 to 4.
    4), and the diagnosis delay for women was 0.
    9 years (95% CI −0.
    4 to 2.
    1).

     Serum IGF-I levels are significantly lower in female patients, and the lowest growth hormone levels are comparable to the size of pituitary adenomas.

     Conclusion In summary, this study shows that the gender difference at the time of diagnosis of acromegaly is smaller.
    In comparison, female patients are slightly older at the time of diagnosis, have a lower IGF-I concentration, and have a longer diagnosis delay than men.
    long.

     Yimaitong compiled and compiled from: Jakob Dal; Benedikte G.
    Skov; Marianne Andersen, et al.
    Sex Differences in Acromegaly at Diagnosis A Nationwide Cohort Study and Meta-Analysis of the Literature.
    Clin Endocrinol.
    2021;94(4):625 -635.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.